Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes

The Effect of Blood Glucose to Different Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01637350

Enrollment

Registered

2012-07-11

Start date

2012-08-31

Completion date

2016-12-31

Last updated

2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

Detailed description

Different digestive tract reconstruction will affect the blood glucose level of gastric cancer with type 2 diabetes. Subtotal gastrectomy with Billroth II reconstruction and total gastrectomy with Roux-en-Y reconstruction may help to improve glycaemic control which includes fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C -peptide and body weight of gastric cancer patients with type 2 diabetes. The investigators will observed fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C -peptide and body weight of the patients preoperation, 14 days postoperation 3 month and 6month postoperation. The investigators will observed the effect of blood glucose to different digestive tract reconstruction after gastrectomy of gastric cancer with type 2 diabetes

Interventions

PROCEDUREdigestive tract reconstruction

Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. 18-75 years old,gastric cancer ,can be performed operation 2. with type 2 diabetes,fasting blood glucose \> 6.1mmol/L 3. without serious underlying diseases which may affect the metabolism and nutrient uptake 4. without serious underlying diseases which may affect anesthesia and operation 5. can be performed subtotal or total gastrectomy, predicted survival period \> 6months 6. no other abdominal operation 7. preoperation consultation 8. informed consent

Exclusion criteria

1. recurrent,metastasis or die 2. patient requests for quit 3. pregnancy

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026